Valuation : IO Biotech, Inc.

Market Cap 43.81M 37.67M 35.44M 32.34M 60.35M 4.15B 60.66M 420M 162M 2.12B 165M 161M 6.76B P/E 2023
-0.95x
P/E 2024 -0.63x
Enterprise Value -14.31M -12.3M -11.57M -10.56M -19.71M -1.36B -19.81M -137M -53.05M -693M -53.72M -52.55M -2.21B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99.69%
Yield 2023 *
-
Yield 2024 -
1 week+9,900.00%
Current month+9,900.00%
3 months-98.82%
6 months-99.97%
Current year-99.98%
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0.7
1 year 0
Extreme 1.0E-6
2.08
3 years 0
Extreme 1.0E-6
2.79
5 years 0
Extreme 1.0E-6
17.88
10 years 0
Extreme 1.0E-6
17.88
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/10/2021
Compliance Officer 58 23/01/2023
Investor Relations Contact - 01/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
05/06/25 Free

Director

35,144 0.0533%
05/06/25 Free

Director

35,144 0.0533%
05/06/25 Free

Director

35,144 0.0533%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+9,900.00%-99.99%-99.99% 7.19K
-0.88%-5.55%-3.06%+13.10% 48.01B
-1.29%-1.22%+404.92%+545.45% 44.44B
-3.20%+0.33%+38.11%+21.39% 42.67B
-1.89%-2.00%+1.45%+82.46% 39.96B
-1.72%-2.61%+13.09%+42.33% 32.75B
-0.17%+3.78% - - 17.74B
-0.07%+1.32%+20.08%+117.95% 16.49B
-0.03%-2.20%+11.29%+31.38% 14.38B
-2.68%-0.56%+73.31%+40.56% 13.4B
Average -1.19%+989.57%+51.02%+88.29% 26.98B
Weighted average by Cap. -1.52%-1.05%+85.03%+132.49%

Financials

2023 2024
Net sales - -
Net income -86.08M -74.01M -69.63M -63.54M -119M -8.16B -119M -825M -319M -4.17B -323M -316M -13.27B -95.49M -82.1M -77.24M -70.49M -132M -9.05B -132M -915M -354M -4.63B -359M -351M -14.72B
Net Debt -141M -121M -114M -104M -194M -13.34B -195M -1.35B -522M -6.82B -528M -517M -21.7B -58.12M -49.97M -47.01M -42.9M -80.06M -5.51B -80.47M -557M -215M -2.82B -218M -213M -8.96B
Logo IO Biotech, Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Employees
80
Date Price Change Volume
08/09/26 $0.000100 0.00% 49,542
04/09/26 $0.000100 0.00% 3,999
03/09/26 $0.000100 +9,900.00% 69,303
02/09/26 $0.000001 0.00% 611
01/09/26 $0.000001 0.00% 21,000

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IOBTQ Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!